The future of immune checkpoint blockade immunotherapy: towards personalized therapy or towards combination therapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. RNA splicing alterations in lung cancer pathogenesis and therapy.Cancer pathogenesis and therapy · 2023
   Review
2. Research progress on black phosphorus hybrids hydrogel platforms for biomedical applications.Journal of biological engineering · 2023
   Review
3. Nanotechnology-based combinatorial phototherapy for enhanced cancer treatment.RSC advances · 2022
   Review
4. The Role of Photodynamic Therapy in Triggering Cell Death and Facilitating Antitumor Immunology.Frontiers in oncology · 2022
   Review
5. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy.Signal transduction and targeted therapy · 2021
   Review

Corrections and comments

• Comment on
  Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.2017

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.